Oncolytic adenoviruses
Open Access
- 1 September 2012
- journal article
- Published by Taylor & Francis in OncoImmunology
- Vol. 1 (6) , 979-981
Abstract
The therapeutic efficacy of oncolytic viruses including adenovirus has been thought to depend mostly on direct viral destruction of tumor cells. However, this view has changed with the discovery th...Keywords
This publication has 10 references indexed in Scilit:
- Induction of Interferon Pathways Mediates In Vivo Resistance to Oncolytic AdenovirusMolecular Therapy, 2011
- Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic AdenovirusMolecular Therapy, 2011
- Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14Nature Medicine, 2010
- Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSFMolecular Therapy, 2010
- Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer PatientsCancer Research, 2010
- VSV replication in neurons is inhibited by type I IFN at multiple stages of infectionVirology, 2005
- Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T CellsThe Journal of Immunology, 2003
- Vesicular Stomatitis Virus (VSV) Therapy of TumorsIUBMB Life, 2000
- A full-length murine 2-5A synthetase cDNA transfected in NIH-3T3 cells impairs EMCV but not VSV replicationVirology, 1990
- Comparative Study of the Efficacy of Different Forms of Interferon Therapy in the Treatment of Mice Challenged Intranasally with Vesicular Stomatitis Virus (VSV)Experimental Biology and Medicine, 1971